332 related articles for article (PubMed ID: 33213170)
1. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study.
Gómez Espín R; Nicolás De Prado I; Gil Candel M; González Carrión M; Rentero Redondo L; Iniesta Navalón C
Rev Esp Enferm Dig; 2021 Feb; 113(2):110-115. PubMed ID: 33213170
[TBL] [Abstract][Full Text] [Related]
2. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
[TBL] [Abstract][Full Text] [Related]
3. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
Proietti E; Pauwels RWM; van der Woude CJ; Doukas M; Oudijk L; Peppelenbosch MP; Grohmann U; Crombag MBS; de Vries AC; Fuhler GM
Inflamm Bowel Dis; 2023 Jul; 29(7):1038-1046. PubMed ID: 35917118
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between Serum Ustekinumab Trough Concentration and Clinical and Biochemical Disease Activity: A Real-World Study in Adult Patients with Crohn's Disease.
Nguyen KM; Mattoo VY; Vogrin S; Basnayake C; Connell WR; Ding NS; Flanagan E; Kamm MA; Lust M; Niewiadomski O; Schulberg JD; Wright EK
Eur J Drug Metab Pharmacokinet; 2023 May; 48(3):271-279. PubMed ID: 36952135
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
[TBL] [Abstract][Full Text] [Related]
10. Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease.
Pan Y; Ahmed W; Mahtani P; Wong R; Longman R; Jeremy Lukin D; Scherl EJ; Battat R
Inflamm Bowel Dis; 2022 Dec; 28(12):1865-1871. PubMed ID: 35212368
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients.
Mechie NC; Burmester M; Mavropoulou E; Pilavakis Y; Kunsch S; Ellenrieder V; Amanzada A
Medicine (Baltimore); 2021 Mar; 100(11):e25111. PubMed ID: 33725990
[TBL] [Abstract][Full Text] [Related]
12. Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn's disease.
Pauwels RWM; Ten Bokkel Huinink S; van der Woude CJ; Doukas M; Oudijk L; de Vries AC
Scand J Gastroenterol; 2023; 58(9):980-987. PubMed ID: 36970968
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
[TBL] [Abstract][Full Text] [Related]
14. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
15. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.
Vasudevan A; Tharayil V; Raffals LH; Bruining DH; Becker M; Murad MH; Loftus EV
Inflamm Bowel Dis; 2024 Apr; 30(4):660-670. PubMed ID: 37071852
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
[TBL] [Abstract][Full Text] [Related]
18. Ustekinumab induction concentrations are associated with clinical and biochemical outcomes at week 12 of treatment in Crohn's disease.
Walshe M; Borowski K; Boland K; Rho S; Stempak JM; Silverberg MS
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e401-e406. PubMed ID: 33731595
[TBL] [Abstract][Full Text] [Related]
19. Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.
Colman RJ; Tsai YT; Jackson K; Boyle BM; Noe JD; Hyams JS; D'Haens GRAM; van Limbergen J; Rosen MJ; Denson LA; Minar P
Inflamm Bowel Dis; 2021 Jun; 27(7):1045-1051. PubMed ID: 32944769
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study.
Rowan CR; Keegan D; Byrne K; Cullen G; Mulcahy HE; Sheridan J; Ryan EJ; de Vries A; D'Haens G; Doherty GA
Aliment Pharmacol Ther; 2018 Aug; 48(3):333-339. PubMed ID: 29920697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
